“Cheap generic versions of current first line treatments, metformin and sulfonylureas, are widely available so why does this not apply to insulin?” ask Professors Gale and Yudkin in their insightful commentary in the BMJ.
Edwin A M Gale, John S Yudkin. Politics of affordable insulin. BMJ 2011; 343:d5675
Endodiabesity 